AMPCX Performance — Amcap Fund, Class C
Data updated: 2026-07-29
AMPCX returned +6.47% year to date and +22.92% over one year to May 2026. Annualised returns are +20.04% over 3 years and +8.98% over 5 years. The fund trailed its US Large Growth category average: $100 invested three years ago grew to $173, against $187 for the category, and to $123 over one year, against $125. Volatility over the past three years was 15.40% a year. In the 12 months to May 2026 the fund lost a net $3.5B, and assets reached $97.21B.
AMPCX Growth of $100
What $100 invested in Amcap Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Growth category average over the same months.
| Period | AMPCX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $123 | $125 |
| 3 years (Jun 2023 – May 2026) | $173 | $187 |
| 5 years (Jun 2021 – May 2026) | $154 | $176 |
| Since data start (Sep 2019 – May 2026) | $225 | $274 |
AMPCX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.47% |
| 1 year | +22.92% |
| 3 years (annualised) | +20.04% |
| 5 years (annualised) | +8.98% |
AMPCX Annual Returns
Calendar-year total returns of Amcap Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +6.47% |
| 2025 | +16.91% |
| 2024 | +20.19% |
| 2023 | +30.01% |
| 2022 | −29.31% |
| 2021 | +22.73% |
| 2020 | +20.52% |
| 2019 (Sep–Dec) | +10.50% |
AMPCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.2% | −2.2% | −6.8% | +12.0% | +4.1% | — | — | — | — | — | — | — |
| 2025 | +3.9% | −3.2% | −7.3% | +1.5% | +7.0% | +6.3% | +2.3% | +1.0% | +2.3% | +2.8% | +0.6% | −0.7% |
| 2024 | +1.4% | +6.4% | +2.5% | −5.0% | +3.3% | +4.1% | +0.5% | +2.0% | +2.1% | −1.6% | +5.2% | −1.7% |
| 2023 | +8.7% | −2.4% | +3.5% | +0.9% | +1.5% | +5.9% | +3.2% | −1.8% | −5.6% | −3.1% | +10.7% | +6.3% |
| 2022 | −10.7% | −3.0% | +0.9% | −11.3% | −1.6% | −8.0% | +9.6% | −4.4% | −8.7% | +4.9% | +5.7% | −5.0% |
| 2021 | −0.5% | +3.1% | +1.9% | +5.0% | +0.1% | +2.7% | +1.9% | +3.1% | −3.5% | +7.5% | −3.1% | +3.1% |
| 2020 | −0.6% | −5.8% | −11.8% | +13.4% | +5.6% | +2.6% | +4.5% | +4.7% | −3.2% | −2.4% | +9.9% | +4.4% |
| 2019 | — | — | — | — | — | — | — | — | −0.4% | +2.5% | +4.7% | +3.4% |
AMPCX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 15.40%
- 3-year Sharpe ratio: 1.01 (vs 4.5% risk-free rate)
- Best month: +11.98% (Apr 2026)
- Worst month: −7.27% (Mar 2025)
AMPCX Fund Flows
Monthly money in and out of Amcap Fund, from SEC Form N-PORT.
- 12-month net flow: −$3.5B
- 12-month gross sales (incl. reinvestments): $14.8B
- Sales ÷ redemptions: 0.81×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $393.4M | $999.3M | −$605.9M |
| Apr 2026 | $455.0M | $4.7B | −$4.2B |
| Mar 2026 | $871.1M | $819.8M | $51.3M |
| Feb 2026 | $943.3M | $828.6M | $114.7M |
| Jan 2026 | $764.2M | $1.5B | −$753.0M |
| Dec 2025 | $4.8B | $1.6B | $3.2B |
| Nov 2025 | $443.5M | $1.0B | −$561.1M |
| Oct 2025 | $489.1M | $1.3B | −$856.6M |
| Sep 2025 | $512.8M | $1.5B | −$1.0B |
| Aug 2025 | $437.0M | $1.1B | −$669.1M |
| Jul 2025 | $461.7M | $1.1B | −$668.5M |
| Jun 2025 | $4.2B | $1.6B | $2.5B |
AMPCX Assets Under Management
Net assets of Amcap Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $97.21B |
| 2026-02-28 | $93.86B |
| 2025-11-30 | $97.95B |
| 2025-08-31 | $94.80B |
| 2025-05-31 | $88.53B |
| 2025-02-28 | $88.64B |
| 2024-11-30 | $91.66B |
| 2024-08-31 | $88.04B |
| 2024-05-31 | $83.64B |
| 2024-02-29 | $85.37B |
| 2023-11-30 | $76.23B |
| 2023-08-31 | $76.22B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.